Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (CN1209068) Hyaluronic acid as DNA carrier for gene therapy and VEGF antisense DNA to treat abnormal retinal vascularization

Office : China
Application Number: 96199290.5 Application Date: 22.10.1996
Publication Number: 1209068 Publication Date: 24.02.1999
Publication Kind : A
Prior PCT appl.: Application Number:PCTAU9600664 ; Publication Number:9715330 Click to see the data
IPC:
A61K 48/00
A61K 47/36
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
30
Macromolecular compounds
36
Polysaccharides; Derivatives thereof
CPC:
C12N 15/1136
A61K 9/0014
A61K 9/0019
A61K 38/00
A61K 47/36
A61K 47/61
A61K 48/00
C07K 14/52
C12N 15/1137
C12N 2310/111
C12N 2310/315
C12N 2799/022
C12N 2799/025
C12Y 304/22027
C12Y 304/23005
Applicants: Hyal Pharmaceutical Australia Ltd.
海欧制药澳大利亚有限公司
Inventors: Piroska Elizabeth Rakoczy
波罗斯卡·伊丽莎白·雷考茨
Ian Jeffrey Constable
伊恩·杰弗里·康斯特伯
Agents: lin xiaogong
永新专利商标代理有限公司
Priority Data: PN6161 23.10.1995 AU
PN9047 01.04.1996 AU
Title: (EN) Hyaluronic acid as DNA carrier for gene therapy and VEGF antisense DNA to treat abnormal retinal vascularization
(ZH) 作为基因治疗所用的DNA载体的透明质酸及治疗异常视网膜血管化的VEGF反义DNA
Abstract: front page image
(EN) The invention provides methods and compositions for gene therapy, including antisense therapy. In one embodiment, the compositions comprise hyaluronic acid to promote uptake of nucleic acid by the target cells. The invention is illustrated with reference to treatment of retinal diseases caused by neovascularisation.
(ZH)

本发明提供了用于基因治疗如反义治疗的方法和组合物。在一个实施方案中,所述的组合物包括透明质酸以促进靶细胞对核酸的吸收。本发明通过参照对由新生血管化所致视网膜病的治疗加以描述。


Also published as:
SG53164EP0859636JP2000507915CA2235685KR1019990066967NZ320006
AU1996072664WO/1997/015330